Our Vision

A vision now within reach, thanks to RNA therapies and lipid-based nanoparticles.

We believe advanced medicine should be accessible to everyone, everywhere,

not someday, but now.

Our Story

Nanofacile’s story began with a question “What if we could make RNA therapy development radically faster and more accessible?”

That question sparked a journey. By 2023, after years of research, and over 140 interviews with scientists, researchers, CEOs, and CTOs around the world, the challenge was clear: RNA therapies were promising but painfully slow, costly, and complex to formulate.

Nanofacile Inc. was officially founded in Montreal in August 2023 by a multidisciplinary team of scientists, engineers, and biologists determined to solve that problem. By breaking nanoparticle encapsulation down to its core, we developed a technology platform to streamline RNA therapy formulation, faster, easier, and designed for real-world scalability.

With support from top Canadian accelerators like Centech and District 3, and backing from forward-thinking investors like V1 Studio, Nanofacile quickly gained traction. Our core technology is now validated and ready to help reshape RNA therapeutic development.

Our mission is simple but ambitious: to empower biotech innovators, CROs, and pharmaceutical companies to accelerate and de-risk RNA therapy development, bringing next-generation treatments to more people, faster.

Who we are ?

Nanofacile is a biotech company redefining how RNA therapies are developed.

We help researchers, CROs, and pharmaceutical teams simplify and speed up lipid-based nanoparticle formulation, one of the most complex bottlenecks in RNA therapy R&D.

Our platform reduces preclinical development time by making encapsulation faster, more precise, and easy to integrate into real-world lab workflows.